Navigation Links
Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
Date:11/20/2007

Frost & Sullivan's industry research concludes, 'Masimo pulse oximetry is

the only vital sign module clinicians ask for by brand'

IRVINE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry, announced it has received a Frost & Sullivan 2007 Industry Best Practices Award, for Pulse Oximetry Leadership -- "ranking number one in the pulse oximetry industry." Frost & Sullivan further recognized "the impressive progression of Signal Extraction Technology (Masimo SET) to the 'gold standard' for reliable pulse oximetry monitoring" in honoring the company.

Superior Technology

Historically, the performance of conventional pulse oximetry, as well as its usefulness in a variety of clinical settings, has been plagued by interfering noise due to patient motion and low peripheral perfusion, which often results in false SpO2 readings and frequent alarms. "Masimo Signal Extraction Technology (SET) eliminates the issues caused by motion artifact and low peripheral perfusion through proprietary signal processing algorithms and sensor technologies," said Frost & Sullivan analyst Mike Arani in his report.

Clinical Preference

Leading clinicians around the world have put the efficacy and reliability of Masimo SET to the test in more than 100 independent and objective peer-reviewed studies that prove Masimo's revolutionary Signal Extraction Technology outperforms all others, even under the most demanding of clinical conditions. "These clinical trials have not only proved the performance superiority of Masimo SET, but time after time, they have also left a lasting impression on the participating clinicians," the report said.

Brand Recognition

Also, according to the Frost & Sullivan report, "Masimo's strong brand recognition has even driven major patient monitoring companies with in-house proprietary SpO2 technologies to offer their multiparameter monitors with the choice of Masimo SET SpO2 module." Today, Masimo SET technology is widely integrated into more than 100 multiparameter monitors and over 40 monitoring brands. "After all, performance superiority is the chief reason Masimo pulse oximetry is the only vital sign module clinicians ask for by brand when purchasing a patient-monitoring product," they added.

Market Achievements

Masimo's rapid market acceptance and market share gains were cited by Frost & Sullivan as visible examples of this combination of superior technology, clinical preference, brand recognition and exceptional brand development success.

In selecting Masimo for the 2007 pulse oximetry brand development strategy leadership award, Frost & Sullivan's analyst team tracked all the major participants in the pulse oximetry industry. The process included in-depth interviews with all market participants, customers and suppliers, along with extensive secondary and technology research to identify best practices within the industry. To determine the final ranking of competitors, Frost & Sullivan measured each on the basis of: development of unique brand strategies, competitor recognition and brand value, participation in industry trade groups, establishment of programs that allow the brand's customers to grow, and increases in customer loyalty. As a result of this ranking, Masimo topped the list of industry competitors.

According to Frost & Sullivan manager Antonio Garcia, "The key to Masimo's strong image lies in its vision of giving caregivers more options and capabilities than they expect. After all, Masimo simply takes the guess work out of pulse oximetry, so clinicians never have to guess what brand is the most reliable."

Joe E. Kiani, Chairman and CEO of Masimo, said, "We are honored to receive this award from Frost & Sullivan. This recognition is especially meaningful because Frost & Sullivan has surveyed the market and responded with research findings that validate what we have heard clinicians saying all along and what our increasing marketshare momentum is a testament to-that clinicians recognize Masimo SET is the best pulse oximetry technology for their patients."

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com.

About Masimo

Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.

Contact:

Tom McCall

Masimo Corporation

949-297-7075

Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad-57, APOD, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpCO, SpMet, and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.


'/>"/>
SOURCE Masimo Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
2. Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume
3. Breaking Studies - Masimos Technologies the Focus of Multiple Clinical Studies at Last Weeks American Society of Anesthesiologists Annual Meeting
4. Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
5. Masimo Corporation Adopts Stockholder Rights Plan
6. Masimo to Present at Piper Jaffray 19th Annual Healthcare Conference
7. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
8. Brooke Franchise Corporation Announces Selected July Results
9. MedThink Communications Retained by NanoBio Corporation
10. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
11. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Therachat , a ... survey in an infographic on the current state of anxiety in support of National ... anxiety, was conducted in April 2017 and benchmarked general anxiety levels as well as ...
(Date:5/22/2017)... Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics ... be administered for a variety of treatments. One or more sedation methods may be ...
(Date:5/22/2017)... PITTSBURGH, PA (PRWEB) , ... May 22, 2017 , ... ... way to write with a pen. "My wife’s hand was damaged in a firework ... invent something that helps people with manual problems." , He then designed and created ...
(Date:5/22/2017)... ... 22, 2017 , ... Faithfully following pop culture, people today are forever in ... shaped through fitness programs. It carries on to skin nourished, pampered and nurtured to ... radiant smile. CDA has found that just like a perfectly cut and ...
(Date:5/21/2017)... ... May 19, 2017 , ... Chris Cornell, 52, was found dead on the night of Wednesday, ... most respected lead singers in the rock industry would take his own life, but the ... investigates how mental illness played a role in the death of Chris Cornell . ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
Breaking Medicine Technology: